MHMichiko Hasegawa

Michiko Hasegawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michiko Hasegawa has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Osamu Ishikawa

    Department of Dermatology Gunma University Graduate School of Medicine Maebashi Japan

    5 shared publications
  • Etsuko Okada

    Department of Dermatology, National Hospital Organization Takasaki General Medical Center

    3 shared publications
  • Atsushi Tamura

    Department of Dermatology, Isesaki Municipal Hospital

    2 shared publications
  • Osamu Tago

    Department of Dermatology Gunma University Graduate School of Medicine Gunma Japan

    2 shared publications
  • Tomoyasu Hattori

    Department of Dermatology Gunma University Graduate School of Medicine Gunma Japan

    2 shared publications
  • A. Tamura

    Department of Dermatology, Gunma University Graduate School of Medicine, 3‐39‐22 Showa‐machi, Maebashi, Gunma 371‐8511, Japan

    1 shared publication

Latest Publications

  • Safety and Efficacy of Topical Use of Imiquimod (Beselna Cream 5%) for the Treatment of Actinic Keratosis : A Retrospective Multicenter Collaborative Clinical Study

    by Masahito Yasuda, Etsuko Okada, Michiko Hasegawa, Yukie Endo, Keiichiro Ryuzaki, Katsuyuki Okada, Atsushi Tamura, Osamu Ishikawa

    日光角化症は,紫外線による表皮細胞の DNA 損傷から生じる表皮内癌であり,有棘細胞癌の早期病変である。近年,人口の高齢化とともにその発症数は増加してきており,早期治療が重要である。2011 年,日光角化症に対しイミキモド(ベセルナクリーム 5%)が保険適応疾患として追加承認された。日光角化症に対するイミキモド外用療法の有効性ならびに安全性を評価するために,2012年 6月から2013 年 6 月までイミキモドにより治療された日光角化症症例を解析する後ろ向き多施設共同臨床研究を行った。対象症例は 46 例,男性 23 例,女性 23 例,平均年齢は 82.2 歳,罹病期間の平均は 29.3 カ月であり,9 例に前治療歴があった。イミキモドは添付文書通りに使用されており,3 回/週で 4 週間外用,4 週間休薬し,効果不十分の場合はもう 1 コース追加された。奏効率は 78%,治療後 12 カ月まで観察できた 18 例では全例で再発はみられなかった。イミキモド外用による有害事象は,局所皮膚反応のみで,1 コース目では 47.8%,2 コース目では 8.7%にみられた。1 例は休薬する必要があったが,中止後速やかに改善していた。これまでの報告と同様,イミキモド外用は有効性が高く,再発率が低いことから,日光角化症に対して非常に有用な治療薬剤であると考える。


  • Clinical analysis of leg ulcers and gangrene in rheumatoid arthritis

    by Michiko Hasegawa, Yayoi Nagai, Yoko Sogabe, Tomoyasu Hattori, Chizuru Inoue, Etsuko Okada, Osamu Tago, Osamu Ishikawa

    Leg ulcers are often complicated in patients with rheumatoid arthritis (RA), however, the etiology is multifactorial. We examined the cases of leg ulceration or gangrene in seven RA patients who were hospitalized over the past 3 years. One patient was diagnosed as having pyoderma gangrenosum. Although vasculitis was suspected in three patients, no histological evidence was obtained from the skin specimens. In these patients, angiography revealed the stenosis or occlusion of digital arteries. In the remaining three patients, leg ulcers were considered to be due to venous insufficiency. Treatment should be chosen depending on the causes of leg ulcers.


  • Bosentan for digital ulcers in patients with systemic sclerosis

    by Yayoi Nagai, Michiko Hasegawa, Tomoyasu Hattori, Etsuko Okada, Osamu Tago, Osamu Ishikawa

    Recurrent digital ulcers are manifestations of vascular disease in patients with systemic sclerosis (SSc). We report six patients with severe digital ulcers who were treated with bosentan administered p.o., 62.5–125 mg daily. The mean duration from the diagnosis of SSc to the initiation of bosentan was 9.5 years, and the observation period after bosentan administration was from 7 months to 4.5 years. In case 1, neither new digital ulcers nor Raynaud’s phenomenon developed for 4.5 years. In case 2, digital ulcers recurred after the discontinuation of bosentan; however, re‐administration of bosentan lead to the improvement. In cases 3–5 with recurrent digital ulcers, no new lesions have developed. In these five patients, pain evaluated by visual analog scale was significantly reduced. In three patients, bosentan was discontinued because of severe liver dysfunction. These results suggest that bosentan is an effective treatment for refractory digital ulcers associated with SSc; however, liver function should be carefully monitored. Compared to the doses of bosentan used to treat pulmonary hypertension, relatively lower doses may effectively control painful digital ulcer/gangrene in patients with SSc.


  • Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis

    by M. Hasegawa, Y. Nagai, A. Tamura, O. Ishikawa

    Background Although digital ulcerations frequently occur in patients with systemic sclerosis (SSc), there have been few reports on the macrovascular involvement. Objectives To evaluate the macrovascular involvement in patients with SSc exhibiting digital ulceration or gangrene. Methods Transfemoral catheter arteriography of the upper and/or lower extremities was performed in eight patients (one man and seven women, age range 42–71 years) with SSc exhibiting digital ulceration or gangrene. The background of the patients, such as autoantibody profiles and vascular risk factors including smoking habits, was also investigated. Results Macrovascular involvement was detected in seven of eight patients. In three of seven patients who underwent arteriography of the upper extremity, occlusion was limited to the digital arteries. Obliteration of the ulnar artery and superficial palmar arch was detected in three of seven patients, and the radial artery in one patient. Only one of five patients who underwent arteriography of the lower extremity showed the occlusion limited to digital arteries of the foot. Occlusion of the posterior tibial artery, dorsalis pedis artery and arcuate artery was detected, each in one patient. Two patients showed occlusion of the plantar arch. Overall, the occlusion of arteries proximal to the digits was demonstrated in four of eight patients. Three of the four patients were positive for antitopoisomerase‐1 antibody and had diffuse cutaneous SSc (dcSSc) with multiple skin ulcers or gangrene. Conclusions Macrovascular involvement as detected with arteriography is not rare in SSc patients with digital ulceration or gangrene. Moreover, the vascular occlusion proximal to the digits seemed to be frequent in antitopoisomerase‐1 antibody‐positive dcSSc patients with multiple skin ulcers or gangrene.


    • 4 July 2002
      • Vol. 12  (4) , 335-9

    The antipsoriatic effect of thiamazole is not accompanied either by significant changes in blood lymphocyte subsets nor by serum concentration of TNF-alpha.

    by Masatoshi Abe, Kazunori Ohnishi, Michiko Hasegawa, Kumi Aoyama, Atsushi Tamura, Chie Kan, Osamu Ishikawa, Masami Murakami

    It has been reported that the antithyroid thiourethylenes, propylthiouracil and methimazole can bring about significant clinical improvement in patients with psoriasis vulgaris. In this paper, we reconfirmed the clinical usefulness of the antithyroid drug thiamazole, which is similar to methimazole, in Japanese patients with psoriasis vulgaris. We further asked whether the clinical improvement was linked to the changes in some immunological parameters or not. To answer this question, we analyzed peripheral blood lymphocyte subsets and measured serum concentrations of TNF-alpha and IL-1beta in 13 patients with psoriasis vulgaris before and during thiamazole administration. The mean percentage of CD4+ HLA-DR+ lymphocytes in the patients was constantly elevated before and 12 weeks after the administration. The patients treated with thiamazole showed a significant increase in the ratio of CD4+/CD8+ at the 4th week, though it declined at the 8th and 12th week. Other lymphocyte subsets showed no significant change during the treatment. The concentrations of serum TNF-alpha exhibited no significant change during thiamazole administration. Serum concentration of IL-1beta was under the detection level. These results indicate that thiamazole may improve the psoriatic lesion via other immune mechanisms, or the effects can not be reflected by the peripheral lymphocyte subsets and cytokine which we investigated.